NCT01170052 - Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2014

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Temsirolimus

Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.

DRUG

Bendamustine

Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.

DRUG

Temsirolimus

Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.

Trial Locations (3)

Dept. of Hematology and Oncology, Charité, Campus Charité Mitte, Berlin

Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin

Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité, Berlin